| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 08/03/2006 | US20060171992 Blood glucose regulating composition |
| 08/03/2006 | US20060171989 Improved delivery of drug formulations, protein drugs, from implanted medical devices, drug is stored as a solid or in concentrated, rather than dilute, solutions; decreased time required for dose of a drug formulation to be released from device; inhibition of gelation, aggregation, or precipitation |
| 08/03/2006 | US20060171988 Method of treatment using foams as artificial lymph nodes |
| 08/03/2006 | US20060171986 Antibiotic coating of implants |
| 08/03/2006 | US20060171965 Fusion proteins of mycobacterium tuberculosis |
| 08/03/2006 | US20060171964 Polypeptides and polynucleotides from coagulase-negative staphylococci |
| 08/03/2006 | US20060171954 Antigen specific activated T-lymphocytes, detection and use |
| 08/03/2006 | US20060171953 Tumour-specific animal proteins |
| 08/03/2006 | US20060171948 Methods of using IL-1 antagonists to reduce C-reactive protein |
| 08/03/2006 | US20060171945 Ip receptor antagonists for the treatment of pathological uterine conditions |
| 08/03/2006 | US20060171944 N-formyl peptide receptor mediation of platelet chemotaxis toward injured cells and activation of immune response |
| 08/03/2006 | US20060171943 Compositions and methods of treating fibrotic disorders |
| 08/03/2006 | US20060171939 Remedy for degenerative intervertebral discs |
| 08/03/2006 | US20060171938 Compositions and methods for enhancing cognitive function |
| 08/03/2006 | US20060171937 Method of treating chronic cardiac disease |
| 08/03/2006 | US20060171934 Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs |
| 08/03/2006 | US20060171931 Modulators of Wnt signalling pathways and screening methods to identify them; muscular dystrophy; inhibitors of soluble Frizzled-related proteins |
| 08/03/2006 | US20060171927 recruiting neurons to the brain, and treating a neurodegenerative condition by injecting nucleic acid construct intraventricularly into subject's brain; Huntington's Disease |
| 08/03/2006 | US20060171922 Helper virus-free herpesvirus amplicon particles and uses thereof |
| 08/03/2006 | US20060171921 Glycosylated interferon |
| 08/03/2006 | US20060171920 derivatization of the drug with 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS) removable under mild basic conditions by attaching a protein or polymer carrier to derivatized drug molecule,such carrier serving for delivery of the drug |
| 08/03/2006 | US20060171919 Targeted polypeptides |
| 08/03/2006 | US20060171918 Apoptosis inducing molecule I |
| 08/03/2006 | US20060171917 Vaccine formulations for intradermal delivery comprising adjuvants and antigenic agents |
| 08/03/2006 | US20060171915 Blood coagulation promoter and blood collection tube |
| 08/03/2006 | US20060171899 Water-stabilized aerosol formulation system and method of making |
| 08/03/2006 | US20060171888 Miniaturized device; substrate with reservoirs, openings; barriers layer covering aperture |
| 08/03/2006 | DE19632862B4 Immunologisch aktive Proteine von Borrelia burgdorferi, dafür kodierende Nukleinsäuren sowie deren Verwendung in Testkits und als Impfstoffe Immunologically active proteins of Borrelia burgdorferi, nucleic acids coding therefor and the use thereof in test kits and as vaccines |
| 08/03/2006 | CA2640343A1 Controlled production and delivery of biologically active agents by gut bacteria |
| 08/03/2006 | CA2596537A1 Molecules and chimeric molecules thereof |
| 08/03/2006 | CA2596276A1 Use of baff to treat th2-mediated conditions |
| 08/03/2006 | CA2596232A1 The use of emip as cancer therapeutics in combination with electron beam irradiation or adjuvant treatment |
| 08/03/2006 | CA2596227A1 Improved modalities for the treatment of degenerative diseases of the retina |
| 08/03/2006 | CA2596058A1 Method of producing coated fine particles |
| 08/03/2006 | CA2595959A1 Methods for treating renal cell carcinoma |
| 08/03/2006 | CA2595942A1 Treatment of degenerative diseases with the x-linked inhibitor of apoptosis |
| 08/03/2006 | CA2595896A1 Inhibitor nucleic acids |
| 08/03/2006 | CA2595894A1 Percutaneously absorbable preparation, percutaneously absorbable preparation holding sheet, and percutaneously absorbable preparation holding equipment |
| 08/03/2006 | CA2595892A1 Ephb receptor-binding peptides |
| 08/03/2006 | CA2595778A1 Anti-muc1 .alpha..beta. antibodies |
| 08/03/2006 | CA2595749A1 Combination therapy with triterpenoid compounds and proteasome inhibitors |
| 08/03/2006 | CA2595679A1 Parameter selected gm-csf, il-3, il-4, il-5 and chimeras thereof for therapeutic and diagnostic purposes |
| 08/03/2006 | CA2595457A1 Control of drug release by transient modification of local microenvironments |
| 08/03/2006 | CA2594502A1 Homogeneous preparations of il-31 |
| 08/03/2006 | CA2594436A1 Methods and compositions for reducing ischemia-derived microvascular damage |
| 08/03/2006 | CA2593801A1 Antibiotic 107891, its factors a1 and a2, pharmaceutically acceptable salts and compositions, and use thereof |
| 08/03/2006 | CA2590974A1 Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis |
| 08/03/2006 | CA2590338A1 Compositions and methods for treating cardiac conditions |
| 08/03/2006 | CA2571899A1 Targeted and high density drug loaded polymeric materials |
| 08/02/2006 | EP1686175A2 Proteins and nucleic acids encoding same |
| 08/02/2006 | EP1686172A2 Myocardial grafts and cellular compositions useful for same |
| 08/02/2006 | EP1686136A1 Novel glycoprotein and medicinal composition containing the same |
| 08/02/2006 | EP1685847A1 Beta-amyloid-analogue-T-cell epitop vaccine |
| 08/02/2006 | EP1685846A1 Antitumor agent |
| 08/02/2006 | EP1685842A2 Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes |
| 08/02/2006 | EP1685833A1 Remedy for diabetes |
| 08/02/2006 | EP1685764A1 Anti-hypertensive functional food products |
| 08/02/2006 | EP1685405A1 Angiogenesis inhibiting molecules and their use in the treatment and diagnosis of cancer |
| 08/02/2006 | EP1685254A2 Oncolytic herpes simplex virus encoding a heterologous nitroreductase |
| 08/02/2006 | EP1685252A2 Use of cell lines to produce active therapeutic proteins |
| 08/02/2006 | EP1685250A1 Proteins involved in signal transduction |
| 08/02/2006 | EP1685236A2 Methods for altering hematopoietic progenitor cell adhesion, differentiation, and migration |
| 08/02/2006 | EP1685160A1 Dry recombinant human alpha 1-antitrypsin formulation |
| 08/02/2006 | EP1685159A2 Tim-3 polypeptides |
| 08/02/2006 | EP1685153A1 Targeting compositions and preparation thereof |
| 08/02/2006 | EP1685085A2 Implantable sensors and implantable pumps and anti-scarring agents |
| 08/02/2006 | EP1684868A1 Treatment of hi-virus infections with oxidised blood proteins |
| 08/02/2006 | EP1684801A1 Recombinant adenylate cyclase toxin of bordetella induces t cell responses against tumoral antigens |
| 08/02/2006 | EP1684799A2 Rescue agents for treating botulinum toxin intoxications |
| 08/02/2006 | EP1684797A1 Vaccine and method for treatment of neurodegenerative diseases |
| 08/02/2006 | EP1684795A1 Methods and agents for the treatment of cancer |
| 08/02/2006 | EP1684794A1 Altering animal waste composition |
| 08/02/2006 | EP1684793A1 Soluble pharmaceutical compositions for parenteral administration comprising a glp-1 peptide and a insulin peptide of short time action for treatment of diabetes and bulimia |
| 08/02/2006 | EP1684792A2 Pharmaceutical formulations for the sustained release of interleukins and therapeutic applications thereof |
| 08/02/2006 | EP1684791A2 Compositions and methods to modulate an immune response to an immunogenic therapeutic agent |
| 08/02/2006 | EP1684790A2 Homogeneous preparations of chimeric proteins |
| 08/02/2006 | EP1684789A2 Mammalian t1r3 sweet taste receptors |
| 08/02/2006 | EP1684788A2 Peptide increasing fusiogenic capacity of a gamete |
| 08/02/2006 | EP1684787A1 Hepatitis c virus inhibitors |
| 08/02/2006 | EP1684786A1 Enhancement of growth hormone levels with a dipeptidyl peptidase iv inhibitor and a growth hormone secretagogue |
| 08/02/2006 | EP1684785A2 B cell-targeted toxins for humoral immune response reduction |
| 08/02/2006 | EP1684784A2 Compositions of a cyclooxygenase-2 selective inhibitor and a neurotrophic factor-modulating agent for the treatment of central nervous system mediated disorders |
| 08/02/2006 | EP1684783A1 Neuroprotective effects of gly-pro-glu following intravenous infusion |
| 08/02/2006 | EP1684782A2 Process for the synchronization of ovulation for timed breeding without heat detection |
| 08/02/2006 | EP1684756A1 Cytokine inhibitory drugs for treatment of macular degeneration |
| 08/02/2006 | EP1684753A2 Neuromuscular blocking agents and antagonists thereof |
| 08/02/2006 | EP1684745A2 Hepatitis c virus inhibitors |
| 08/02/2006 | EP1684743A1 Composition and method for treating macular degeneration |
| 08/02/2006 | EP1684741A2 Methods of using and compositions comprising pde4 modulators for the treatment and management of asbestos-related diseases and disorders |
| 08/02/2006 | EP1684736A1 Dna damage repair inhibitors for treatment of cancer |
| 08/02/2006 | EP1684727A1 Macromolecular drug complexes having improved stability and therapeutic use of the same |
| 08/02/2006 | EP1684720A2 Introducing aerosol into a ventilator circuit |
| 08/02/2006 | EP1684719A2 Alpha 1-antitrypsin compositions and treatment methods using such compositions |
| 08/02/2006 | EP1684706A2 Genes differentially expressed by acutely isolated resident progenitor cells of the human white matter |
| 08/02/2006 | EP1684703A2 Methods and compositions for treating mcp-1 related pathologies |
| 08/02/2006 | EP1684692A2 Pigment epithelium-derived factor, novel biological activity and methods of use |
| 08/02/2006 | EP1684690A2 Methods of using and compositions comprising a jnk inhibitor for the treatment and management of asbestos-related diseases and disorders |
| 08/02/2006 | EP1684624A2 Human prostate cancer cell factor(s) that induce stem cell commitment and osteogenesis |
| 08/02/2006 | EP1639101A4 Odor control compositions and methods |
| 08/02/2006 | EP1561468A4 Pharmaceutical antidiabetic composition |